EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RANK, RANKL and osteoprotegerin in arthritic bone loss



RANK, RANKL and osteoprotegerin in arthritic bone loss



Brazilian Journal of Medical and Biological Research 38(2): 161-170



Rheumatoid arthritis is characterized by the presence of inflammatory synovitis and destruction of joint cartilage and bone. Tissue proteinases released by synovia, chondrocytes and pannus can cause cartilage destruction and cytokine-activated osteoclasts have been implicated in bone erosions.

(PDF emailed within 0-6 h: $19.90)

Accession: 012477017

Download citation: RISBibTeXText

PMID: 15785827

DOI: /S0100-879X2005000200004



Related references

Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women. Menopause 14(5): 913-918, 2007

Structure-based development of an osteoprotegerin-like glycopeptide that blocks RANKL/RANK interactions and reduces ovariectomy-induced bone loss in mice. European Journal of Medicinal Chemistry 145: 661-672, 2018

Receptor Activator of Nuclear Transcription Factor NF-B (RANK), Its Ligand RANKL, and Natural Inhibitor of RANKL Osteoprotegerin (OPG) in the Blood Serum of Patients with Primary Bone Tumors. Bulletin of Experimental Biology and Medicine 163(4): 478-481, 2017

RANK, RANKL and osteoprotegerin in bone biology and disease. Current Reviews in Musculoskeletal Medicine 2(1): 56-64, 2009

The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. Journal of Endocrinological Investigation 32(4 Suppl): 6-9, 2010

The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. Expert Review of Cardiovascular Therapy 4(6): 801-811, 2006

Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292(4): 490-495, 2004

Role of RANKL-RANK/osteoprotegerin pathway in cardiovascular and bone disease associated with HIV infection. Aids Reviews 16(3): 123-133, 2015

Role of RANKL-RANK/osteoprotegerin molecular complex in bone remodeling and its immunopathologic implications. Indian Journal of Endocrinology and Metabolism 15(3): 175-181, 2011

Effects of osteoprotegerin, RANK and RANKL on bone destruction and collapse in avascular necrosis femoral head. American Journal of Translational Research 8(7): 3133-3140, 2016

The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications. Bulletin du Cancer 98(7): 837-846, 2011

Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review). Molecular Medicine Reports 11(5): 3212-3218, 2016

The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells. Carcinogenesis 32(11): 1634-1640, 2011

Estrogens modulate RANKL-RANK/osteoprotegerin mediated interleukin-6 effect on thyrotoxicosis-related bone turnover in mice. Hormone and Metabolic Research 43(4): 236-240, 2011

Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin. Bone 45(4): 669-676, 2009